The new cleanroom, designed and built by WHP, is part of ADC Bio’s new bioconjugation facility in the UK.
A new cleanroom facility, designed and built by WHP, is a key part of ADC Bio’s construction of a new bioconjugation facility at its site in Deeside, North Wales, United Kingdom for the commercial production of antibody drug conjugates (ADCs). ADCs are a class of emerging biotherapeutics that require a bespoke infrastructure to ensure strict compliance with the highest global regulatory standards. The new facility, which includes support areas for washing, depyrogenation, thawing, and buffer preparation, is a stringently controlled environment operated under cGMP regulations.
WHP, a multi-disciplinary engineering company, was awarded the £5-million (approximately US$6.3 million) contract in December 2017. WHP’s scope of work covered the design and build, including test and validation of a state-of-the-art containment manufacturing cleanroom within an existing 6500-m2 high tech facility, along with new quality control and process development laboratories.
Computer aided design work encompassed cleanroom architecture, mechanical and electrical components, and process and critical utilities systems. Complex, zoned heating, ventilation, and air-conditioning systems maintain segregation, cleanliness, air pressures, and other environmental controls, in compliance with regulations.
A key feature of the project was the installation of a bespoke, low-maintenance toxic waste system, developed by WHP to remove cleanroom waste to a holding tank, where it is transported to an off-site incinerator. This system incorporates dry break couplers to seal off both ends of the pipeline to prevent the possibility of any onsite contamination.
“The new cleanroom meets ADC Bio’s need to expand operations at Deeside beyond R&D to include safe, secure, and highly efficient manufacturing capabilities,” said WHP’s project manager, Chris Douglas, in a July 15, 2019 press release.
Source: WHP Engineering
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.